Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: Findings from the ASTRONAUT trial

Stephen J. Greene, Gregg C. Fonarow, Scott D. Solomon, Haris Subacius, Aldo P. Maggioni, Michael Böhm, Eldrin F. Lewis, Faiez Zannad, Mihai Gheorghiade*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

Aims This study sought to investigate regional variation in clinical characteristics, therapy utilization, and post-discharge outcomes among patients hospitalized for heart failure (HHF) enrolled in the multinational ASTRONAUT (Aliskiren Trial on Acute Heart Failure Outcomes) trial. Methods and results The ASTRONAUT trial randomized 1615 HHF patients with ejection fraction ≤40% to aliskiren or placebo. Enrolled patients were from Eastern Europe (n = 495, 30.7%), Asia/Pacific (n = 439, 27.2%), Western Europe (n = 395, 24.5%), Latin America (n = 163, 10.1%), and North America (n = 123, 7.6%). Marked differences were seen across geographic regions in terms of baseline demographics, vital signs, laboratory tests, co-morbidity burden, and use of guideline-recommended therapies. All-cause death at 12 months ranged from 7.3% in North America to 26.7% in Asia/Pacific, with differences largely driven by sudden cardiac death. Rates of repeat HHF at 12 months ranged from 22.7% in Latin America to 43.9% in North America. After adjustment for patient characteristics, region was an independent predictor of death at 12 months, with highest risk in Asia/Pacific (hazard ratio 3.04, 95% confidence interval 1.47-6.29, compared with North America) and lowest risk in North America and Western Europe. There was no association between region and the composite of cardiovascular mortality or HHF. Conclusion For patients enrolled in this HHF trial, baseline characteristics and risk of death differed markedly by geographic region. Rates of death and repeat HHF demonstrated a general inverse relationship. Global differences in patient characteristics and outcomes should be accounted for when designing future HHF clinical trials.

Original languageEnglish (US)
Pages (from-to)591-600
Number of pages10
JournalEuropean Journal of Heart Failure
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2015

Keywords

  • Clinical trial
  • Global
  • Heart failure
  • Outcomes
  • Region

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: Findings from the ASTRONAUT trial'. Together they form a unique fingerprint.

Cite this